Rethinking ovarian cancer: recommendations for improving outcomesSebastian Vaughan, Frances R. Balkwill, Jermaine Coward et al.|Nature reviews. Cancer|2011Cited by 1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerDavid D.L. Bowtell, Frances R. Balkwill, Katherine B. Chiappinelli et al.|Nature reviews. Cancer|2015Cited by 1.4k
<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study GroupKathryn Alsop, Gillian Mitchell, Sián Fereday et al.|Journal of Clinical Oncology|2012Cited by 1.2k
Prognostically relevant gene signatures of high-grade serous ovarian carcinomaRoel G.W. Verhaak, Matthew Meyerson, Pablo Tamayo et al.|Journal of Clinical Investigation|2012Cited by 591
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancerRowan Miller, Lucy Yates, Alexandra Léary et al.|Annals of Oncology|2020Cited by 478